

# Sebastian Scholl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8566562/publications.pdf>

Version: 2024-02-01

40  
papers

744  
citations

623188

14  
h-index

552369

26  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1249  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1569-1583.	1.2	3
2	Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1481-1492.	1.2	1
3	Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2539-2548.	1.2	2
4	Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3191-3202.	1.2	14
5	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	2.5	21
6	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. <i>Blood</i> , 2021, 138, 244-244.	0.6	60
7	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. <i>Cells</i> , 2020, 9, 2493.	1.8	49
8	Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial. <i>Blood</i> , 2020, 136, 1-3.	0.6	4
9	Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e129-e131.	1.7	19
10	Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 337-345.	1.2	17
11	Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0150632.	1.1	34
12	Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2603-2610.	1.2	7
13	Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis. <i>Annals of Hematology</i> , 2016, 95, 1899-1901.	0.8	5
14	Detection of <i>Enterococcus</i> spp. in bronchoalveolar lavage fluid of patients with high-risk neutropenia: May it be ignored?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1133-1136.	1.2	0
15	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. <i>Blood</i> , 2016, 128, 1066-1066.	0.6	5
16	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016, 128, 589-589.	0.6	11
17	Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1661-1668.	1.2	10
18	Lower gastrointestinal bleeding in a patient with Crohn's disease and plasma cell leukemia in remission. <i>Annals of Hematology</i> , 2015, 94, 2063-2065.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Different clones of acute leukemia after successful treatment of Hodgkin's disease. <i>Annals of Hematology</i> , 2014, 93, 2077-2079.	0.8	0
20	Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1391-1397.	1.2	5
21	Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO). <i>Blood</i> , 2014, 124, 280-280.	0.6	8
22	Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. <i>Annals of Hematology</i> , 2013, 92, 1071-1077.	0.8	14
23	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1397-1404.	1.2	13
24	The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 605-615.	1.2	9
25	The E3 ubiquitin ligase TRAF2 can contribute to TNF- $\alpha$ resistance in FLT3-ITD-positive AML cells. <i>Leukemia Research</i> , 2013, 37, 1557-1564.	0.4	10
26	Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm's Combined Prospective Analysis by the German AML Intergroup. <i>Journal of Clinical Oncology</i> , 2012, 30, 3604-3610.	0.8	121
27	Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory FLT3-ITD/691L mutation. <i>British Journal of Haematology</i> , 2012, 157, 483-492.	1.2	46
28	Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1293-1300.	1.2	15
29	Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. <i>Annals of Hematology</i> , 2011, 90, 473-475.	0.8	10
30	Clinical implications of molecular genetic aberrations in acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 491-505.	1.2	31
31	Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase $\beta$ . <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 861-872.	1.2	11
32	Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 years with acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2008, 80, 208-215.	1.1	70
33	Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations. <i>Leukemia and Lymphoma</i> , 2007, 48, 2418-2423.	0.6	4
34	Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia. <i>Annals of Hematology</i> , 2007, 86, 763-765.	0.8	6
35	Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. <i>Leukemia Research</i> , 2005, 29, 849-853.	0.4	31
36	Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. <i>Transfusion</i> , 2005, 45, 1676-1683.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. <i>Translational Research</i> , 2005, 145, 295-304.	2.4	24
38	Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 279-283.	1.2	7
39	Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 711-718.	1.2	5
40	Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 704-710.	1.2	16